Zinc Supplementation Improves the Outcome of Chronic Hepatitis C and Liver Cirrhosis
Authors:
- Hiroshi MatsumuraHMHiroshi Matsumura
- Hitomi NakamuraHNHitomi Nakamura
- Shu OshiroSOShu Oshiro
- Yasuo ArakawaYAYasuo Arakawa
- Junpei HayashiJHJunpei Hayashi
- Naoki SekineNSNaoki Sekine
- Kazushige NireiKNKazushige Nirei
- Hiroaki YamagamiHYHiroaki Yamagami
- Masahiro OgawaMOMasahiro Ogawa
- Noriko NakajimaNNNoriko Nakajima
- Shuichi AmakiSAShuichi Amaki
Open Access
- 28 October 2009
- journal article
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 45 (3) , 292-303
Abstract
We treated patients with C-viral chronic hepatitis (CH) and liver cirrhosis (LC) with polaprezinc and determined prospectively the effect on long-term outcome. 62 patients were enrolled. Of these, 32 were administered 1.0 g polaprezinc and the remainder were not administered polaprezinc. We measured the serum zinc concentrations using conventional atomic absorption spectrometry and conducted a prospective study to determine the long-term outcome of the polaprezinc therapy. Changes of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in the polaprezinc administration group were significantly lower than those of the untreated group. The decrease in platelet count was clearly less than that of the untreated group. The factors that inhibited increases in serum zinc concentrations following administration of polaprezinc included low serum zinc concentration states. Furthermore, the reductions of AST and ALT levels in the low zinc group were significantly greater than those of the high zinc group. When the patients who were administered polaprezinc were divided into two groups whose zinc concentrations increased (zinc responders) or remained stable or decreased (zinc non-responders), the zinc responders had a clearly lower cumulative incidence of HCC than the zinc non-responders. We conclude zinc supplementation improved the long-term outcome in C-viral CH and LC patients.Keywords
This publication has 28 references indexed in Scilit:
- The NS5A Protein of Hepatitis C Virus Is a Zinc MetalloproteinJournal of Biological Chemistry, 2004
- Liver cirrhosis and “liver” diabetes mellitus are linked by zinc deficiencyMedical Hypotheses, 2004
- Metal Contents in the Liver of Patients with Chronic Liver Disease Caused by Hepatitis C VirusOncology, 2003
- Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis.2001
- Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis CJournal of Viral Hepatitis, 2001
- Overview of Zinc Absorption and Excretion in the Human Gastrointestinal TractThe Journal of Nutrition, 2000
- Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosisHepatology, 1996
- Zinc Supplementation Reduces Blood Ammonia and Increases Liver Ornithine Transcarbamylase Activity in Experimental CirrhosisHepatology, 1992
- Serum and urinary zinc in fulminant hepatic failureJournal of Gastroenterology and Hepatology, 1989
- Guidelines for essential trace element preparations for parenteral use. A statement by an expert panel. AMA Department of Foods and Nutrition.1979